Skip to content

Research at St Andrews

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Research output: Contribution to journalArticlepeer-review

Author(s)

Michael Mullen, Xu Yu Jin, Anne Child, A Graham Stuart, Matthew Dodd, José Antonio Aragon-Martin, David Gaze, Anatoli Kiotsekoglou, Li Yuan, Jiangting Hu, Claire Foley, Laura Van Dyck, Rosemary Knight, Tim Clayton, Lorna Swan, John D R Thomson, Guliz Erdem, David Crossman, Marcus Flather, AIMS Investigators

School/Research organisations

Abstract

BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome.

METHODS: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794.

FINDINGS: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events.

INTERPRETATION: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications.

Close

Details

Original languageEnglish
Pages (from-to)2263-2270
JournalLancet
Volume394
Issue number10216
Early online date10 Dec 2019
DOIs
Publication statusPublished - 21 Dec 2019

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

    Arnold, N. D., Pickworth, J. A., West, L. E., Dawson, S., Carvalho, J. A., Casbolt, H., Braithwaite, A. T., Iremonger, J., Renshall, L., Germaschewski, V., McCourt, M., Bland-Ward, P., Kowash, H., Hameed, A. G., Rothman, A. M. K., Frid, M. G., Roger Thompson, A. A., Evans, H. R., Southwood, M., Morrell, N. W. & 7 others, Crossman, D. C., Whyte, M. K. B., Stenmark, K. R., Newman, C. M., Kiely, D. G., Francis, S. E. & Lawrie, A., 15 Nov 2019, In: Nature Communications. 10, 18 p., 5183.

    Research output: Contribution to journalArticlepeer-review

  2. Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

    Crossman, D. & Rothman, A. M. K., 18 Sep 2018, In: Journal of Thoracic Disease. 10, Suppl 26, p. S3084-S3087

    Research output: Contribution to journalEditorialpeer-review

  3. Dietary docosahexaenoic acid reduces oscillatory wall shear stress, atherosclerosis and hypertension, most likely mediated via an IL-1-mediated mechanism

    Alfaida, M., Chamberlain, J., Rothman, A., Crossman, D. C., Villa-Uriol, M-C., Hadoke, P., Wu, J., Schenkel, T., Evans, P. & Francis, S., 3 Jul 2018, In: Journal of the American Heart Association. 7, 13, 19 p., e008757.

    Research output: Contribution to journalArticlepeer-review

  4. ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages

    Layhadi, J. A., Turner, J., Crossman, D. & Fountain, S. J., 1 Feb 2018, In: The Journal of Immunology. 200, 3, p. 1159-1168

    Research output: Contribution to journalArticlepeer-review

  5. Canakinumab for atherosclerotic disease

    MRC-ILA Heart investigators, Rothman, A. M., Morton, A. C. & Crossman, D. C., 11 Jan 2018, In: New England Journal of Medicine. 378, 2, p. 197-8 2 p.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. School reopening without robust COVID-19 mitigation risks accelerating the pandemic

    Gurdasani, D., Alwan, N. A., Greenhalgh, T., Hyde, Z., Johnson, L., McKee, M., Michie, S., Prather, K. A., Rasmussen, S. D., Reicher, S., Roderick, P. & Ziauddeen, H., 10 Mar 2021, In: The Lancet.

    Research output: Contribution to journalLetter

  2. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3

    Global Burden of Disease Health Financing Collaborator Network & Cevik, M., 23 Apr 2020, In: Lancet. Online First, 32 p.

    Research output: Contribution to journalArticlepeer-review

  3. The COVID-19 vaccines rush: participatory community engagement matters more than ever

    Burgess, R. A., Osborne, R. H., Yongabi, K. A., Greenhalgh, T., Gurdasani, D., Kang, G., Falade, A. G., Odone, A., Busse, R., Martin-Moreno, J. M., Reicher, S. & McKee, M., 10 Dec 2020, In: The Lancet. In Press

    Research output: Contribution to journalComment/debatepeer-review

  4. The UK needs a sustainable strategy for COVID-19

    Gurdasani, D., Bear, L., Bogaert, D., Burgess, R. A., Busse, R., Cacciola, R., Charpak, Y., Colbourn, T., Drury, J., Friston, K., Gallo, V., Goldman, L. R., Greenhalgh, T., Hyde, Z., Kuppalli, K., Majumder, M. S., Martin-Moreno, J. M., McKee, M., Michie, S., Mossialos, E. & 16 others, Nouri, A., Pagel, C., Pimenta, D., Popescu, S., Priesemann, V., Rasmussen, A. L., Reicher, S., Ricciardi, W., Rice, K., Silver, J., Smith, T. C., Wenham, C., West, R., Yamey, G., Yates, C. & Ziauddeen, H., 9 Nov 2020, In: The Lancet. In Press, 2 p.

    Research output: Contribution to journalComment/debate

  5. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    RESTART Collaboration & Sullivan, F., 29 Jun 2019, In: Lancet. 393, 10191, p. 2613-2623 11 p.

    Research output: Contribution to journalArticlepeer-review

ID: 264469584

Top